To examine the influence of Iba1 on the prognostic impact of CD63 in glioblastomas, patients included in the TCGA dataset were dichotomized based on the median mRNA levels of Iba1 and 25th percentile level of CD63 resulting in four groups: 1) CD63low/Iba1low, 2) CD63low/Iba1high, 3) CD63high/Iba1low, and 4) CD63high/Iba1high (Fig. 4i). Here, AIF1 is linked to glioblastoma.